EACH OPPORTUNITY IS AN ADVISED CLIENT OF ACCELERIS CAPITAL
Acceleris Capital have 20 years experience in advising technology SMEs with a track record of delivering value. The senior team have deep experience in working with early stage ventures with over £120m introduced through EIS, over 100 transactions completed, 70 companies listed on AIM and multiple exit events for private companies.
FREE TO INVEST
THERE ARE NO FEES TO INVESTORS ON ANY INTRODUCED OPPORTUNITY
There are no fees to investors. All invested capital will go to the investee company and there is no carry on exit. We believe in complete transparency and alignment, ensuring ongoing communication between stakeholders and the company. Our fees are derived from the provision of genuine value add services for the lifecycle of the venture.
A COMMUNITY OF EXPERIENCE, INTELLIGENCE AND RESPECT
Our investor members pool their collective experience and support to our early-stage ventures. We all appreciate the risks, time-taken and hard-work needed to be successful. This community of partners can facilitate introductions and provide experience to our investees while our investors benefit from access to a powerful network of peers.
The Enterprise Investment Scheme was founded to accelerate the commercialisation of true UK innovation. Acceleris have always believed in this mission, have delivered market-leading results and provided significant positive impacts to society.
We believe that a combination of intelligent entrepreneurs, respectful risk-tolerant capital and world-class advisors reduces the risk of early-stage investment and leads to stronger, more valuable companies. By working together in a respectful way, by communicating transparently and by working hard, early-stage companies can thrive.
Acceleris are an FCA regulated advisory house committed to driving value and supporting early-stage technology. We are not brokers and ensure that each opportunity introduced to investors is one of our corporate advisory clients.
OPEN EIS OFFERS
Improving health in cities through a better, more sustainable food system.
Opportunity to invest in the immediate expansion of an established vertical farming business who boast 100+ b2b contracts across London. Through using smart agriculture technology to build high-tech farms in key urban areas of multiple deprivation, the company can bring fresh food closer to end-consumers.
Improving the quality of life for allergy sufferers
Commercialising the work of the world-leading authorities on allergy diagnostics. Reacta is now generating revenues in the US, UK & Canada and has recently located to an expanded manufacturing facility. Reacta is raising funds to expand and take advantage of its leading position on Oral Food Challenge diagnosis to support the effectiveness of allergy treatments.
Bite Club Kitchen
Scientifically driven nutrition and meal planning
Successfully launched manufacturing business specialising in scientifically supported nutrition. Opportunity to invest in the growth of the business as it expands to a chain of nationwide gyms and coffee shops. Embracing modern technology, the company intends to become the nations first nationwide meal planning service
Working to eliminate toxicity in cancer therapeutics
Through direct experience in the NHS and with a leading Antibody Drug Conjugate ("ADC") sector specialist, the BiVictriX team has developed the Bi-Cygni platform. The platform is results in a marked increase in cancer target selectivity, addressing one of the key issues concerning the targeted oncology therapeutics industry.
ACCELERIS ACCEPT INVESTMENTS FROM CERTIFIED HIGH NET WORTH INDIVIDUALS, SOPHISTICATED, FAMILY OFFICER OR INSTITUTIONAL INVESTORS. ALL INVESTORS MUST APPLY TO ACCELERIS CAPITAL PRIOR TO RECEIVING FURTHER INFORMATION. YOUR CAPITAL IS AT RISK.